Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28095838 | 0.84 | CA12 (0.43) | ZDHHC20ZDHHC2PSMB5TSHRCA1 | |
| SCHEMBL2004205 | 0.83 | ZDHHC20 (0.46) | ZDHHC20ZDHHC2PSMB5TSHRCA1 | |
| SCHEMBL19801200 | 0.83 | ALDH1A1 (0.38) | ZDHHC20ZDHHC2TSHRCA1CA12 | |
| SCHEMBL14413797 | 0.83 | ZDHHC20 (0.38) | ZDHHC20ZDHHC2PSMB5TSHRALDH1A1 | |
| SCHEMBL18643288 | 0.82 | ZDHHC20 (0.33) | ZDHHC20ZDHHC2TSHRALDH1A1 | |
| SCHEMBL14528303 | 0.81 | ZDHHC20 (0.34) | ZDHHC20ZDHHC2TSHRCA1CA12 | |
| SCHEMBL16776772 | 0.79 | ZDHHC20 (0.56) | ZDHHC20ZDHHC2PSMB5TSHRCA1 | |
| SCHEMBL633117 | 0.79 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2PSMB5TSHRCA1 | |
| SCHEMBL2560026 | 0.79 | ZDHHC20 (0.47) | ZDHHC20ZDHHC2PSMB5TSHRCA1 | |
| SCHEMBL27841026 | 0.79 | ZDHHC20 (0.38) | ZDHHC20ZDHHC2PSMB5TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | ZDHHC20 958/4885ZDHHC2 905/4885PSMB5 3458/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ZDHHC20 1528/4885ZDHHC2 816/4885PSMB5 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.